Peterborough City Hospital

The trials here

What the 16 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer3 trials
• Childhood cancers2 trials
• Coronary artery disease2 trials
• Stroke2 trials
• Bladder cancer1 trial
• Deep vein thrombosis and pulmonary embolism1 trial
• Heart failure1 trial
• Idiopathic pulmonary fibrosis1 trial
• Liver cirrhosis1 trial
• Lung cancer1 trial
• Lupus (SLE)1 trial
• Ovarian cancer1 trial
• and 3 more

Phase

• Phase 39 trials
• Phase 23 trials
• Phase 2/31 trial

Status

• Active, not recruiting7 trials
• Completed4 trials
• Recruiting4 trials
• Terminated1 trial

Lead sponsor

• Janssen Research & Development, LLC3 trials
• Hoffmann-La Roche2 trials
• AbbVie1 trial
• Cambridge University Hospitals NHS Foundation Trust1 trial
• Craig Anderson1 trial
• and 8 more

Running trials

• Recruiting

  A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

  NCT07438496· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

  NCT06200207· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT05085028· Phase 3· Imperial College London· Source

  Contact: Sarah Treece

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)

  NCT04576455· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)

  NCT04546009· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

  NCT03150576· Phase 2/3· Cambridge University Hospitals NHS Foundation Trust· Source

  Contact: Karen McAdam (principal investigator)

• Active, not recruiting

  Study of Tumour Focused Radiotherapy for Bladder Cancer

  NCT02447549· Phase 2· Institute of Cancer Research, United Kingdom· Source

• Active, not recruiting

  Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome

  NCT01934725· SECRETO Study Consortium· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers1 recruiting
• Lung cancer1 recruiting
• Lupus (SLE)1 recruiting
• Metastatic breast cancer1 recruiting
• Triple-negative breast cancer1 recruiting

Closed trials

• Completed

  DELIVER Study in a Population With Clinical Suspicion of Liver Cirrhosis

  NCT07035158· Owlstone Ltd· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  Optimal Post Tpa-Iv Monitoring in Ischemic Stroke

  NCT03734640· Craig Anderson· Source

• Completed

  A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

  NCT04209855· Phase 3· AbbVie· Source